Extended Data Fig. 3: Lpcat3AKO does not affect adipocyte and whole-body glucose homeostasis.
From: Dietary control of peripheral adipose storage capacity through membrane lipid remodelling
(a) Immunoblot analysis of phospho-Akt/PKB and rpS6 in iWAT of 12-week-old NCD-fed control and Lpcat3AKO mice after i.p. injection with insulin (1 U kg–1). Total Akt/PKB and rpS6 served as sample processing controls. (b) Coronal, sagittal, and transverse views of 12-week-old NCD-fed control and Lpcat3AKO mice by positron emission tomography–computed tomography (PET–CT) imaging 1 h post-injection with 18F-FDG and insulin (1 U kg–1). (c) 18F-FDG uptake (× 106 pCi g–1 tissue) in the indicated insulin-target tissues (n = 4, 4). (d) glucose tolerance tests (GTT; 1.5 g kg–1) and (e) insulin tolerance tests (ITT; 0.75 U kg–1) were performed on 18-week-old NCD-fed control and Lpcat3AKO mice (n = 10, 9). (f) Respiratory exchange ratios (RER) of 18-week-old NCD-fed control and Lpcat3AKO mice were monitored over a period of 48 h in Oxymax metabolic cages (n = 16, 15). Data are presented as mean ± SEM.
